Medication-assisted treatment and HIV/AIDS: Aspects in treating HIV-infected drug users

AIDS

Volumn 24, Issue 3, 2010, Pages 331-340

  Bruce, R Douglas ^a   Kresina, Thomas F ^b   McCance Katz, Elinore F ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretroviral treatment; Buprenorphine; HIV AIDS; Methadone; Naltrexone; Substance abuse treatment

Indexed keywords

ACAMPROSATE; ALCOHOL; ATAZANAVIR; BUPRENORPHINE; DARUNAVIR; DELAVIRDINE; DISULFIRAM; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; ILLICIT DRUG; INDINAVIR; INTEGRASE INHIBITOR; LOPINAVIR; MARAVIROC; METHADONE; NALTREXONE; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; TIPRANAVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALCOHOLISM; DISEASE TRANSMISSION; DRUG DEPENDENCE; DRUG USE; EVIDENCE BASED MEDICINE; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL CARE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; SUBSTANCE ABUSE; TOBACCO DEPENDENCE; UNITED STATES;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG INTERACTIONS; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; PREJUDICE; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES;

EID: 75649115728     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833407d3     Document Type: Review

References (73)

1. Hendershot CS, Stoner SA, George WH, Norris J. Alcohol use, expectancies, and sexual sensation seeking as correlates of HIV risk behavior in heterosexual young adults. Psychol Addict Behav 2007; 21:365-372.
2. Chander G, Josephs J, Fleishman JA, Korthuis PT, Gaist P, Hellinger J, Gebo K. Alcohol use among HIV-infected persons in care: results of a multisite survey. HIV Medicine 2008; 9:196-202.
3. Zule WA, Costenbader E, Commers CM, Meyer MJ Jr, Riehman K, Poehlman J, Wechsberg WM. Stimulant use and sexual risk behaviors for HIV in rural North Carolina. J Rural Health 2007; 23 (Suppl):73-78.
4. Shannon K, Kerr T, Bright V, Gibson K, Tyndall MW. Drug sharing with clients as a risk factor for increased violence and sexual and drug related harms among survival sex workers. AIDS Care 2008; 20:228-234.
5. Center for Disease Control and Prevention (CDC). HIV and AIDS in the United States: a picture of today's epidemic. Available at: http://www.cdc.gov/ hiv/topics/surveillance/united-states.htm accessed 1/26/2009
6. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Text Revision American Psychiatric Association (publishers), Washington, DC; 1994.
7. Bruce RD, Altice FL. Clinical care of the HIV-infected drug user. Infect Dis Clin N America 2007; 21:149-179.
8. Sylvestre DL, Loftis JM, Hauser P, Genser S, Cesari H, Borek N, et al. Co-occurring hepatitis C, substance use and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health 2004; 81:719-734.
9. Sorensen J, Copeland A. Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend 2000; 59:17-31.
10. Substance Abuse and Mental Health Services Administration (SAMHSA). Substance abuse treatment for persons with co-occurring disorders. Treatment Improvement Protocol (TIP) 42. DHHS Publication No. 05-3993. 2005 Rockville Maryland available at http://www.dpt.samhsa.gov/reports/index.htm accessed 03/04/2008.
11. Substance Abuse and Mental Health Services Administration, SAMHSA. Medication-assisted treatment for opioid addiction in Opioid Treatment Programs. Treatment Improvement Protocol (TIP) 43. DHHS Publication No. 05-4048. 2005 Rockville Maryland available at http://www.dpt.samhsa.gov/reports/in-dex.htm accessed 03/04/2008
12. Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, SAMHSA. Medication-assisted treatment for opioid addiction. 2008 state profiles. November 2008 Rockville Maryland available at http:// www.dpt.samhsa.gov/reports/index.htm.
13. Substance Abuse and Mental Health Services Administration, SAMHSA. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) 40. DHHS Publication No. 04-3939. 2004 Rock-ville Maryland available at http://www.dpt.samhsa.gov/ reports/ index.htm accessed 03/04/2008.
14. Basu S, Smith-Rohrberg D, Bruce RD, Altice FL. Models of integrating buprenorphine therapy into HIV care. Clin Infect Dis 2006; 42:716-721.
15. Fiellin DA, O'Connor PG. Clinical practice. Office-based treatment of opioid-dependent patients. N Engl J Med 2002; 347:817-823.
16. Tallarida RJ, Cowan A. The affinity of morphine for its phar-macologic receptor in vivo. J Pharmacol Exp Ther 1982; 222:198-201.
17. Baros AM, Latham PK, Moak DH, Voronin K, Anton RF. What role does the measuring medication compliance play in evaluating the efficacy of naltrexone? Alcohol Clin Exp Res 2007; 31:596-603.
18. Greenstein RA, Evans BD, McLellan AT, O'Brien CP. Predictors of favorable outcome following naltrexone treatment. Drug Alcohol Depend 1983; 12:173-180.
19. Samet JH, Walley AY, Bridden C. Illicit drugs, alcohol and addiction inhuman immunodeficiency virus. Panminerva Medicine 2007; 49:67-77.
20. Weiss RD, Kueppenbender KD. Combining psychosocial treatment with pharmacotherapy for alcohol dependence. J Clin Psychopharmacol 2006; 26 (Suppl 1):S37-42.
21. Substance Abuse and Mental Health Services Administration (SAMHSA). In Incorporating alcohol pharmacotherapies into medical practice. Treatment Improvement Protocol (TIP) XX. DHHS Publication No. 08-XXXX. Rockville Maryland 2008 available at http://www.dpt.samhsa.gov/reports/index. htm.
22. Suh JJ, Pettinati HM, Kampman KM, O'Brien CP. The status of disulfiram: a half of a century later. J Clin Psychopharmacol 2006; 26:290-302.
23. Fuller RK, Wiliford WO, Lee KK, Derman R. Veterans Administration cooperative study of disulfiram in the treatment of alcoholism: study design and methodological considerations. Control Clin Trials 1984; 5:263-273.
24. Madan A, Parkinson A, Faiman MD. Identification of the human P-450 enzymes responsible for the sulfoxidation and thiono-oxidation of diethyldithiocarbamate methyl ester: role of P-450 enzymes in disulfiram bioactivation. Alcohol Clin Exp Res 1998; 22:1212-1219.
25. O'Malley SS, Froehlich JC. Advances in the use of naltrexone: an integration of preclinical and clinical findings. Rec Dev Alcohol 2003; 16:217-245.
26. Patinati HM, Rabinowitz AR. Choosing the right medication for the treatment of alcoholism. Curr Psychiatry Rep 2006; 8:383-388.
27. Mason BJ. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry 2001; 62 (Suppl 20):42-48.
28. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al., COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295:2003-2017.
29. Sohler NL, Wong MD, Cunningham WE, Cabral H, Drainoni ML, Cunningham CO. Type and pattern of illicit drug use and access to healthcare services for HIV-infected people. AIDS Patient Care STDS 2007; 21 (Suppl 1):S68-76.
30. Begre S, von Bardeleben U, Ladewig D, Jaquet-Rochat S, Cosendai-Savary L, Golay KP. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol 2002; 22:211-215.
31. Wang JS, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)-and (S)-methadone in vitro. Drug Metab Dispos 2003; 31:742-747.
32. Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharma-cokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr 2006; 41:563-572.
33. McCance-Katz EF, Rainey PM, Jatlow P, Friedland GH. Metha-done effects on zidovudine disposition (AIDS Clinical Trials Group 262). J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:435-443.
34. McCance-Katz EF, Rainey PM, Friedland G, Kosten TR, Jatlow P. Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am J Addict 2001; 10:296-307.
35. Rainey PM, Friedland G, McCance-Katz EF, Andrews L, Mitchell SM, Charles C, Jatlow P. Interaction of methadone with didanosine and stavudine. J Acquir Immune Defic Syndr 2000; 24:241-248.
36. Rainey PM, Friedland GH, Snidow JW, McCance-Katz EF, Mitchell SM, Andrews L, et al. The pharmacokinetics of metha-done following co-administration with a lamivudine/zidovu-dine combination tablet in opiate-dependent subjects. Am J Addict 2002; 11:66-74.
37. Friedland G, Rainey P, Jatlow P, et al. Pharmacokinetics (PK) of didanosine (ddI) from encapsulated enteric coated bead formulation (EC) vs. chewable tablet formulation in patients (pts) on chronic methadone therapy. In 14th International AIDS Conference; International AIDS Society: Barcelona, Spain. 2002.
38. Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999; 13:957-962.
39. Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG, Back DJ, et al. Pharmacokinetic interactions of nevira-pine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Dis 2001; 33:1595-1597.
40. Stocker H, Kruse G, Kreckel P, Herzmann C, Arasteh K, Claus J, Jessen H, et al. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48:4148-4153.
41. Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG, Back DJ, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the nonnucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharm 2001; 51:213-217.
42. Pinzani V, Faucherre V, Peyriere H, Blayac JP. Methadone withdrawal symptoms with nevirapine and efavirenz. Ann Pharmacother 2000; 34:405-407.
43. Package Insert. Aptivus (r), tipranavir. Boehringer Ingelheim Pharmaceuticals, Inc.: Ridgefield, CT; 2005.
44. Bruce RD, McCance-Katz E, Karasch ED, Moody DE, Morse GD. Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin Infect Dis 2006; 43: S216-223.
45. McCance-Katz EF, Moody DE, Morse GD, Friedland GH, Pade P, Baker J, et al. Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis 2006; 43 (Suppl 4):S224-234.
46. McCance-Katz EF, Moody DE, Smith PF, Morse GD, Friedland G, Pade P, et al. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopina-vir/ritonavir, and ritonavir. Clin Infect Dis 2006; 43 (Suppl 4): S235-246.
47. Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM. Rifampin-in-duced methadone withdrawal. N Engl J Med 1976; 294:1104-1106.
48. Cobb MN, Desai J, Brown LS Jr, Zannikos PN, Rainey PM. The effect of fluconazole on the clinical pharmacokinetics of methadone. Clin Pharmacol Ther 1998; 63:655-662.
49. Berk SI, Litwin AH, Arnsten JH, Du E, Soloway I, Gourevitch MN. Effects of pegylated interferon alfa-2b on the pharmaco-kinetic and pharmacodynamic properties of methadone: a prospective, nonrandomized, crossover study in patients co-infected with hepatitis C and HIV receiving methadone maintenance treatment. Clin Ther 2007; 29:131-138.
50. Baker J, Rainey PM, Moody DE, Morse E, Ma Q, McCance-Katz EF. Interactions between buprenorphine and anti-retrovirals: Nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine and tenofovir. Am J Addict (in press).
51. McCance-Katz EF, Moody DE, MorseE, Ma Q,RaineyP.Lack of clinically significant drug interactions between nevirapine and buprenorphine. Am J Addict (in press).
52. Bruce RD, Altice FL. Three case reports of a clinical pharma-cokinetic interaction with buprenorphine and atazanavir plus ritonavir. AIDS 2006; 20:783-784.
53. McCance-Katz EF, Moody DE, Morse GD, Ma Q, DiFrancesco R, Friedland G, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend 2007; 91:269-278.
54. Bruce RD, Altice FL, Moody DE, Lin S, Fang WB, Sabo JS, et al. Pharmacokinetic interactions between buprenorphine/nalox-one and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug Alcohol Depend 2009; 105:234-239.
55. Kresina TF, Flexner CW, Sinclair J, Correia MA, Stapleton JT, Adeniyi-Jones S, et al. Alcohol use and HIV pharmacotherapy. AIDS Res Hum Retroviruses 2002; 18:757-770.
56. Edenberg HJ. The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants. Alcohol Res Health 2007; 30:5-13.
57. Flexner CW, Cargill V, Sinclair J, Kresina TF, Cheever L. Alcohol use can result in enhanced drug metabolism in HIV pharma-cotherapy. AIDS Patient Care STDS 2001; 15:57-58.
58. McDowell JA, Chittick GE, Stevens CP, Edwards KD, Stein DS. Pharmacokinetic interaction of abacavir (1592U89) and etha-nol in human immunodeficiency virus-infected adults. Antimi-crob Agents Chemother 2000; 44:1686-1690.
59. Trivedi CD, Pitchumoni CS. Drug-induced pancreatitis: an update. J Clin Gastroenterol 2005; 39:709-716.
60. Pineda JA, Macias J. Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy. J Antimicrobl Chemother 2005; 55:417-419.
61. Bruce RD, Altice FL, Friedland GH. Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice. Exp Rev Clin Pharm 2008; 1:115-127.
62. Wynn GH, Cozza KL, Zapor MJ, Wortmann GW, Armstrong SC. Med-psych drug-drug interactions update. Antiretrovirals, part III: antiretrovirals and drugs of abuse. Psychosomatics 2005; 46:79-87.
63. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharma-codynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38:41-57.
64. Yuan R, Flockhart DA, Balian JD. Pharmacokinetic and phar-macodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. J Clin Pharm 1999; 39:1109-1125.
65. Tran JQ, Gerber JG, Kerr BM. Delavirdine: clinical pharmaco-kinetics and drug interactions. Clin Pharmacokinet 2001; 40:207-226.
66. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharma-cokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998; 35:275-291.
67. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug Safety 1998; 18:83-97.
68. Le Tiec C, Barrail A, Goujard C, Taburet AM. Clinical pharma-cokinetics and summary of efficacy and tolerability of ataza-navir. Clin Pharmacokinet 2005; 44:1035-1050.
69. Yong WP, Ramirez J, Innocenti F, Ratain MJ. Effects of keto-conazole on glucuronidation by UDP-glucuronosyltransferase enzymes. Clin Cancer Res 2005; 11:6699-6704.
70. Court MH. Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods En-zymol 2005; 400:104-116
71. United States Federal Code, SEC. 3501. NOTE: 21 USC 801 Drug Abuse Treatment Act of 2000 (DATA 2000) available at http://buprenorphine.samhsa.gov/. /fulllaw.html accessed 03/ 04/2008.
72. Sullivan LE, Bruce RD, Haltiwanger D, Lucas GM, Eldred L, Finkelstein R, Fiellin DA. Initial strategies for integrating buprenorphine into HIV care settings in the United States. Clin Infect Dis 2006; 43 (Suppl 4):S191-S196.
73. Buchacz K, Rangel M, Blacher R, Brooks JT. Changes in the clinical epidemiology of HIV infection in the United States: implications for the clinician. Curr Infect Dis Rep 2009; 11:75-83.